Newron announces US initiation of its ENIGMA-TRS 2 Phase III global study of evenamide for patients with treatment-resistant ...
Zacks Investment Research on MSN
Why TriMas (TRS) is a top growth stock for the long term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
TriMas Corporation’s TRS performance continues to be dragged down by the lackluster performance of its packaging segment. The segment’s top-line growth has been in the negative territory over the past ...
TRS is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of TRS shares has increased $0.12 since the market last closed. This is a 0.39% ...
Fintel reports that on December 5, 2025, BWS Financial maintained coverage of TriMas (NasdaqGS:TRS) with a Buy recommendation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback